This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Background: Type 2 diabetes, Obesity and low grade inflammation are becoming worldwide epidemics. The gut microbiota has been
identified as a potential contributor to the development of metabolic diseases. Gut microbiota alteration using spectrum specific
antibiotics can prevent progression of high sucrose diet (HSD) mediated obesity and diabetes, through microbial metabolites and
inflammatory mediators like adipokines.
Aim: To study the effect of modulating the gut microflora by oral administration of spectrum specific antibiotics targeting delivery to
small intestine and colon in HSD induced obesity and insulin resistance.
Methods: Rats were fed HSD with or without antibiotics for 60 days. The physiological and biochemical parameters, fecal microbiota
composition, Short chain fatty acids (SCFAs), Liver biochemistry, histopathology and gene expression of various G-protein coupled
receptors (GPCRs) and various adipokines were investigated.
Results: Simultaneous administration of HSD and antibiotics has shown significant improvements in glucose tolerance and obesity
associated parameters like hypercholesterolemia and hypertryglyceremia as compared to HSD. The qPCR study of fecal samples
showed increased in gram positive bacteria and reduction in gram negative bacteria, which shows that restoration of commensal
microflora in direction to improvement in obesity and insulin sensitivity. Treatment had reduce the effect of Lipopolysaccharide
content, which further reduced immune receptors, GPCRs expression along with reduced the expression of proinflammatory
cytokines. Gut microbiota manipulation towards decreased inflammation and insulin resistance needs to be further explored for its
therapeutic applications in order to treat the metabolic complications.
Parth Rajput has completed his M.Sc. in Biotechnology from Sardar Patel University (SPU). He is currently pursuing Ph.D. from Institute of Science, Nirma University. His work is mainly focused on the gut microbiota and its alteration in diet induced obesity and diabetes. He has published three research papers in peer reviewed international journals. He has presented his work at more than 25 national and international conferences and presented lectures at nationally.